Source-grounded facts extracted from Glucotrack, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Glucotrack, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 15, 2026, the Company received a second letter from Nasdaq notifying the Company that its Form 10-Q for the period ended March 31, 2026, indicates that the Company no longer meets the $2,500,000 minimum stockholders’”
Glucotrack, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“May 11, 2026, Glucotrack, Inc. (the “Company”) received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company”
Glucotrack, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $4.3 million compared to a net loss of $6.8 million for the first quarter of.
“Net Loss: Net loss for the first quarter of 2026 was $4.3 million compared to a net loss of $6.8 million for the first quarter of 2025.”
Glucotrack, Inc. issued 1,300,000 shares of common stock to an investor for exchange of Partitioned Note for no additional consideration.
“the Company and the Investor further agreed to exchange the Partitioned Note for an aggregate of 1,300,000 shares of the Company's common stock, no par value per share”
Glucotrack, Inc. entered into Exchange Agreement with an investor (effective 2026-04-29).
“On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).”
Glucotrack, Inc. issued 895,000 shares of common stock.
“Under the Exchange Agreement, the Company and the Investor further agreed to exchange the Partitioned Note for an aggregate of 895,000 shares of the Company’s common stock, no par value per share (the “Exchange Shares”).”
Glucotrack, Inc. entered into Exchange Agreement with an investor (the "Investor") (effective 2026-04-13).
“On April 13, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note (the “Original Note”) previously issued to the Investor in the principal amount of $3,600,000.”
Glucotrack, Inc. incurred loan of $600,000.
“On April 13, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note (the “Original Note”) previously issued to the Investor in the principal amount of $3,600,000. Pursuant to the Exchange Agreement, the Company and the Investor partitioned a new promissory note in the original principal amount of $600,000 (the “Partitioned Note”) from the Original Note.”
Glucotrack, Inc. reported full year ended December 31, 2025 results: net income Net loss for the full year 2025 was $19.4 million.
“Glucotrack, Inc. (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025.”
Glucotrack, Inc. issued common warrants to purchase 2,067,182 shares of warrant to the Investor for aggregate gross proceeds from the Private Placement of approximately $4.0 million.
“and together with the Pre-Funded Warrant Shares, the “Warrant Shares”) of Common Stock. The Company received aggregate gross proceeds from the Private Placement of approximately $4.0 million, before deducting estimated placement agent commissions and expenses in connection with the Private Placement, which are payable by the Company. The Securities Purchase Agreement”
Glucotrack, Inc. issued 1,033,591 pre-funded warrants of warrant to the Investor for $3.87 per Pre-Funded Warrant less the exercise price per Pre-Funded Warrant of $0.001 per share.
“Closing, the Company issued 1,033,591 pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,033,591 shares (the “Pre-Funded Warrant Shares”) of common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $3.87 per Pre-Funded Warrant less the exercise price per Pre-Funded Warrant of $0.001 per share, and (ii) common warrants to”
Glucotrack, Inc. entered into Securities Purchase Agreement with an investor valued at approximately $4.0 million (effective 2025-12-29).
“On December 29, 2025, Glucotrack, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”) for a private placement of securities”
Glucotrack, Inc. issued $3,600,000 principal amount of convertible note to the Investor for $3,000,000 purchase price.
“On September 12, 2025 (the “ Issue Date ”), Glucotrack, Inc. (the “ Company ”) entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”), with an investor (the “ Investor ”), pursuant to which the Company issued a Convertible Promissory Note (the “ Note ”) to the Investor in the principal amount of $3,600,000 for a purchase price of $3,000,000.”
Glucotrack, Inc. incurred convertible notes of $3,600,000 at no interest maturing twelve (12) month anniversary of the Issue Date, or the date of closing of a Qualified Financing.
“On September 12, 2025 (the “ Issue Date ”), Glucotrack, Inc. (the “ Company ”) entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”), with an investor (the “ Investor ”), pursuant to which the Company issued a Convertible Promissory Note (the “ Note ”) to the Investor in the principal amount of $3,600,000 for a purchase price of $3,000,000.”
Glucotrack, Inc. issued common stock to Sixth Borough Capital Fund, LP for up to $20.0 million of the Company’s common stock.
“On September 11, 2025, Glucotrack, Inc. (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) and a registration rights agreement (the “ Registration Rights Agreement ”), with Sixth Borough Capital Fund, LP (the “ Investor ”), pursuant to which the Investor has committed to purchase up to $20.0 million of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”)”
Glucotrack, Inc. engaged CBIZ CPAs P.C. as its auditor.
“pproved the engagement of CBIZ CPAs P.C. (“CBIZ”) as the Company’s independent registered public accounting firm for”
Glucotrack, Inc. dismissed Grant Thornton as its auditor.
“On July 18, 2025, the Company dismissed Grant Thornton as the Company’s independent registered public accounting firm, effective immediately.”
Glucotrack, Inc. engaged CBIZ CPAs P.C. as its auditor.
“approved the engagement of CBIZ CPAs P.C. (“CBIZ”) as the Company’s independent registered public accounting firm for the Company’s fiscal year ended December 31, 2025, effective July 18, 2025.”
Glucotrack, Inc. dismissed Fahn Kanne & Co. Grant Thornton Israel as its auditor.
“On July 18, 2025, the Company dismissed Fahn Kanne & Co. Grant Thornton Israel (“Grant Thornton”) as the Company’s independent registered public accounting firm, effective immediately.”
Glucotrack, Inc.: Effected a one-for-sixty reverse stock split via Certificate of Amendment to Certificate of Incorporation (effective 2025-06-13).
“Glucotrack, Inc., a Delaware corporation (the “Company”), filed with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Certificate of Amendment”), which became effective at 4:30 p.m. on June 13, 2025 (the “Effective Time”), to effect a one-for-sixty (1:60) reverse stock split”
Glucotrack, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(d)(4)(B)).
“April 2, 2025, the Company received a letter from Nasdaq (the “Notice”) notifying the Company that as a result of non-compliance with the Bid Price Rule, Nasdaq Qualifications Listing Staff (the “Staff”) has determined to delist the Company’s securities. In accordance with the appeal procedures set forth in the Nasdaq Listing 5800 Series, the Company intends to timely submit a hearing request to the Panel on or before April 9, 2025, which will stay the suspension of the Company’s securities pending the final Panel determination or any extensions they may provide. However, there can be no assur”
Glucotrack, Inc.: Filed Certificate of Amendment to effect a one-for-twenty reverse stock split, effective February 3, 2025 (effective 2025-02-03).
“filed with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Certificate of Amendment”), which became effective at 4:30 p.m. on February 3, 2025”
Peter C. Wulff was appointed as Chief Financial Officer at Glucotrack, Inc..
“In connection with Mr. Cardwell’s resignation, on January 28, 2025, the Board appointed Peter C. Wulff as Chief Financial Officer of the Company.”
James Cardwell resigned as Chief Financial Officer at Glucotrack, Inc..
“On January 27, 2025, James Cardwell informed the Board of Directors (the “Board”) of Glucotrack, Inc. (the “Company”) that he was resigning as Chief Financial Officer of the Company, effective immediately.”
Glucotrack, Inc.: Amended Certificate of Incorporation to increase authorized common stock from 100,000,000 to 250,000,000 shares (effective 2025-01-03).
“the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware, and such amendment became effective immediately.”
Glucotrack, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 31, 2024, Nasdaq Stock Market LLC (“Nasdaq”) notified Glucotrack, Inc. (the “Company”) that for at least the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until June 30, 2025, to regain compliance with the Bid Price Rule. If at any time before June 30, 2025, the bi”
John Ballantyne was appointed as director at Glucotrack, Inc..
“On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.”
Paul V. Goode was appointed as director at Glucotrack, Inc..
“On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.”
Andrew Sycoff resigned as Director at Glucotrack, Inc..
“On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.”
Shimon Rapp resigned as Director at Glucotrack, Inc..
“On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.”
Andrew K. Balo was appointed as independent board member at Glucotrack, Inc..
“On June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors as an independent board member.”
Glucotrack, Inc. shareholders voted on Frequency of Non-Binding Advisory Votes on Executive Compensation at the 2024-04-26 meeting.
“Proposal 5 – Frequency of Non-Binding Advisory Votes on Executive Compensation The Company’s stockholders indicated, on an advisory basis, the preferred frequency of future non-binding advisory votes on the compensation of the Company’s named executive officers as follows: Every One (1) Year Every Two (2) Years Every Three (3) Years Abstentions 2,213,593 531,688 8,138,410 5,154,080”
Glucotrack, Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2024-04-26 meeting.
“Proposal 4 – Ratification of Independent Registered Public Accountant The Company’s stockholders ratified the previous appointment by the Audit Committee of the Board of Fahn Kanne & Co”
Glucotrack, Inc. shareholders approved Reverse Stock Split at the 2024-04-26 meeting.
“Proposal 3 – Reverse Stock Split The Company’s stockholders approved of an amendment to Article IV of the Company’s Certificate of Incorporation”
Glucotrack, Inc. shareholders approved Election of Directors at the 2024-04-26 meeting.
“The final results of the voting were as follows: Director Votes For Votes Against Abstentions Broker Non-Vote Dr. Robert Fischell 10,793,666 134,682 5,109,423 1,932,226 Luis Malave 10,793,666 122,745 5,121,360 1,932,226 Andrew Sycoff 10,805,663 5,231,471 637 1,932,226 Shimon Rapps 10,786,853 5,231,531 19,387 1,932,226 Allen Danzig 10,793,726 122,685 5,121,360 1,932,226 Erin Carter 10,793,806 122,745 5,121,220 1,932,226”
Glucotrack, Inc. shareholders approved 2024 Equity Incentive Plan at the 2024-04-26 meeting.
“Proposal 1 – 2024 Equity Incentive Plan The Company’s 2024 Equity Incentive Plan was approved. The final results of the voting were as follows: Votes For Votes Against Abstentions Broker Non-Votes 9,989,257 885,365 5,163,149 1,932,226”
Glucotrack, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“November 24, 2023, the Company received a letter from Nasdaq notifying the Company that it has been granted an additional 180 calendar days, or until May 20, 2024 (the “Extended Compliance Period”), to regain compliance with the Minimum Bid Price Requirement in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time during the Extended Compliance Period, the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance with the Minimum Bid”
James S Cardwell was appointed as Chief Financial Officer at Glucotrack, Inc..
“On October 11, 2023, the Company appointed James S Cardwell, 63, as Chief Financial Officer of the Company, effective immediately.”
Jolie Kahn resigned as Chief Financial Officer at Glucotrack, Inc..
“Effective as of October 6, 2023, Jolie Kahn resigned as Chief Financial Officer of GlucoTrack, Inc. (the “Company”) to pursue other career interests.”
Erin Carter was appointed as Director and Audit Committee Chair at Glucotrack, Inc..
“On August 25, 2023, the Board of Directors of GlucoTrack, Inc. appointed Erin Carter as a director to serve until her successor is elected and duly qualifies.”
Glucotrack, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“May 26, 2023, GlucoTrack, Inc . (the “Company”) received a letter from Nasdaq that it no longer complies with Rule 5550(a)(2) of Nasdaq’s Listing Rules (the “Rules”) which require listed securities to maintain a minimum bid price of $1 per share. Based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets this requirement. However, the Rules also provide the Company a compliance period of 180 calendar days in which to regain compliance. Pursuant to Rule 5810(c)(3)(C) if at any time during this 180 day period the closing bid price of the Company’s sec”
Glucotrack, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).
“common stock with gross proceeds to the Company of approximately $10.0 million, before deducting underwriting discounts and other estimated expenses paid by the Company. The deficiency cured was the November 22, 2022 notice from Nasdaq that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) since its third quarter 2022 Form 10-Q reported stockholders’ equity under the $2.5 million required minimum. The Company acknowledges that Nasdaq will continue to monitor the Company’s ongoing compliance with the stockholders’ equity requirement and, if at the time of its next periodic r”
Glucotrack, Inc. entered into a underwriting with Aegis Capital Corp. valued at approximately $10.0 million (effective 2023-04-13).
“ompany entered into an underwriting agreement with Aegis Capital Corp. on April 13, 2023. The Company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, which may include,”
Glucotrack, Inc. shareholders rejected Nonbinding Say on Pay at the 2023-03-31 meeting.
“Nonbinding Say on Pay 2,844,095.00 5,205,181.00 82,262.00 488,583.00 18.34”
Glucotrack, Inc. shareholders approved Ratify Auditor at the 2023-03-31 meeting.
“Ratify Auditor 8,612,584.00 7,481.00 56.00 0.00 55.55”
Glucotrack, Inc. shareholders approved Election of Directors at the 2023-03-31 meeting.
“DIR # VOTES FOR VOTES WITHHELD BROKER NON-VOTE % VOTES FOR Dr. Robert Fischell 2,881,036.00 5,250,502.00 488,583.00 18.58 Luis Malave 2,880,918.00 5,250,620.00 488,583.00 18.58 Andrew Sycoff 2,945,847.00 5,185,691.00 488,583.00 19.00 Shimon Rapps 2,882,073.00 5,249,465.00 488,583.00 18.59 Allen Danzig 2,880,916.00 5,250,622.00 488,583.00 18.58”
Glucotrack, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).
“February 7, 2023, Nasdaq issued a letter to the Company granting an extension until May 22, 2023 to obtain compliance with the Listing Rule 5550(b) (the “Rule”), which requires a minimum $2,500,000 stockholders’ equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations, notice of noncompliance with which was provided by Nasdaq to the Company on November 22, 2022. Nasdaq has granted the Company an extension to comply through either one or both of an acquisition or equity capital raise on or before May 22, 2023.”
Glucotrack, Inc. received a nasdaq noncompliance notice notice regarding shareholders.
“January 4, 2023, GlucoTrack, Inc. (the “Company”) received a notification from Nasdaq that since it had not held an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end ended December 31, 2021, it no longer complies with our Listing Rules (the “Rules”) for continued listing. Under our Rules the Company has 45 calendar days to submit a plan to regain compliance and if plan is accepted, Nasdaq can grant an exception of up to 180 calendar days from the fiscal year end, or until June 29, 2023, to regain compliance. The Company has already submitted a plan”
Glucotrack, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 22, 2022, Nasdaq provided notice that pursuant to Nasdaq Listing Rule 5550(b)(1), GlucoTrack, Inc. (the “Company”) is required to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. Since its 10-Q for the period ended September 30, 2022 reported stockholders’ equity of $2,355,000, and as of November 22, 2022, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations, the Company no longer complies with the Rule. The Company has a 45-day period ending on January 6, 2023 to submit a plan of compli”
James P. Thrower PhD changed role as Vice President of Engineering at Glucotrack, Inc..
“In connection with the Company’s previously announced plans to migrate certain aspects of product development to the United States, James P. Thrower PhD, Vice President of Engineering, will be assuming Mr. Shushan’s responsibilities.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.